BRP-199

BRP-199 is a small molecule therapeutic candidate being developed by Bioron Pharma for the treatment of Rett Syndrome. Rett Syndrome is a rare, severe neurodevelopmental disorder primarily affecting females, typically caused by mutations in the MECP2 gene, leading to a loss of motor and communication skills. BRP-199 is currently in Phase 2 clinical development, which the sponsor has characterized as a pivotal study. While the specific molecular target and mechanism of action have not been publicly disclosed by Bioron Pharma, the drug is intended to address the core neurological deficits associated with the condition.